Each quarter, Locust Walk’s deal team compiles key statistics and trends on strategic transactions and financings. Our 2026 Q2 Market Conditions Report applies the latest data to analyze the current landscape in life sciences deals.

Licensing activity remained active in Q2 2026 as capital continued to concentrate around early-stage innovation and large strategic partnerships despite moderating deal volume. 

• Globally, licensing remained near record levels in Q2 2026 despite a ~23% decline in deal volume, with average deal size reaching a record ~$1.7B as capital increasingly concentrated into fewer, larger strategic transactions. 

• China remained the most important driver of global licensing economics, with average deal size surging to ~$2.9B (+42% QoQ) as activity concentrated into fewer, higher-value early-stage transactions. 

• Licensing structures became increasingly back-end weighted in Q2 2026 despite continued expansion in headline deal values, with upfront consideration declining to a series low. 

• M&A surged to record quarterly levels in Q2 2026 at ~$80B across 34 transactions, both the highest in the period, while EU/UK licensing contracted sharply, reflecting a more selective partnering environment. 

Capital markets strengthened further in Q2 2026, with IPO proceeds reaching a 3-yr high, U.S. public equity sharply outperforming, and EU/UK venture financing surging 5x on the $2.1B Isomorphic Labs round. 

• U.S. Markets: The financing environment accelerated meaningfully in Q2 2026, with IPO proceeds reaching a three-year high of ~$3.1B across 7 deals, follow-on activity strengthening to ~$11B, and total public and private financing growing to ~$19.2B. 

• APAC Capital Markets: The markets recovered from the Q1 selloff, with China posting a second consecutive $1B+ venture quarter at $1.2B and deal volume reaching a three-year high, while Japan and South Korea reached new equity market highs even as biotech indices lagged broadly. 

• European/UK Capital Markets: Venture financing rebounded sharply to ~$3.3B in Q2 2026 — more than 5x the prior quarter — driven overwhelmingly by Isomorphic Labs’ $2.1B AI-focused Series B, lifting EU/UK’s global venture value share to a period-high ~24%. 

2026 Q2 closed the first half of the year on a more selective note, with licensing capital concentrating into fewer, larger, back-end weighted transactions, M&A surging to record quarterly levels, and capital markets strengthening further on a three-year IPO high and a surge in EU/UK venture financing, signaling a more disciplined but still durable biopharma dealmaking environment. 

We invite you to read our report and welcome the opportunity to discuss its contents with you.